(CRL) Charles River Laboratories International Reports Short of Consensus
Charles River Laboratories International Inc.’s (CRL) first quarter 2010 earnings (excluding special items) of 45 cents per share fell short of the Zacks Consensus Estimate of 47 cents. This was 22.4%...
View Article(DCTH) The Decade of Biotech: Two Hot Biotech Sectors and Eight Ways to Profit
I expect the 2010s to be the “Decade of Biotech.” In 2020, we’ll look back at the past 10 years in amazement at how many medical advances were achieved. And we’ll likely snicker at some of the...
View Article(CRL) Charles River Announces Deal to Buy China’s WuXi
If you’re a healthcare stocks junkie, you may have caught the news… U.S. clinical research company Charles River Laboratories International (NYSE: CRL) announced a deal to buy its Chinese rival, WuXi...
View Article(CVD) Big Pharmaceutical Companies Outsourcing Research and Development
by Tony D’Altorio, Investment U Research Thursday, October 14, 2010 Big pharmaceutical companies seem to be taking tips from an unlikely source these days. A decade ago, big mining companies had a big...
View Article(GS) How to Unlock Gains From Corporate America
by Marc Lichtenfeld, Investment U’s Senior Analyst Wednesday, October 27, 2010: Issue #1375 Corporate America has a problem. It has too much cash. Hang on… having too much cash isn’t bad, right? On the...
View Article(JCP) Activist Investors: Follow the Smart Money And Grab an Extra 21% Per Year
by Marc Lichtenfeld, Investment U’s Senior Analyst Wednesday, October 20, 2010: Issue #1370 Every year, a tiny group of investors quietly outperform the stock market by more than 20 percentage points....
View Article(AZN) AstraZeneca Shares in Neutral Lane
We are maintaining our Neutral recommendation on AstraZeneca (AZN) with a target price of $49.00. The stock carries a Zacks #3 Rank (Hold rating) in the short run. AstraZeneca performed disappointingly...
View Article(ARIA) ARIAD Pharmaceuticals Closes Offering of Shares
ARIAD Pharmaceuticals, Inc. (ARIA) recently announced the closure of its previously announced public offering. ARIAD Pharma priced the public offering of 15.3 million common shares at $19.60 per share,...
View Article(BSTC) BioSpecifics Technologies Annouces Positive Data on Xiaflex
BioSpecifics Technologies (BSTC) recently announced positive top line data from a phase IIa study on Xiaflex for the potential treatment of frozen shoulder syndrome (FSS) in adults. BioSpecifics has a...
View Article(ELN) Elan Responds to Royalty Pharma Offer
Elan Corporation’s (ELN) Board of Directors recently responded to Echo Pharma Acquisition Limited’s (“Royalty Pharma”) offer to acquire Elan’s shares under Rule 2.5 of the Irish Takeover Rules. Elan...
View Article(ALKS) Pipeline Progress at Alkermes
Alkermes (ALKS) recently announced encouraging top-line data from a phase II study (n=142) on ALKS 5461. The study evaluated the safety and efficacy of ALKS 5461 across two doses for the treatment of...
View Article
